WHO Calls for Inclusion of Pregnant and Lactating Women in TB Research, vaccine trials

New Delhi: The World Health Organization has urged the global health community to prioritize pregnant and lactating women in tuberculosis (TB) research and vaccine trials. Each year, around 200,000 women in pregnancy or postpartum develop TB, yet they are often excluded from studies—creating major evidence gaps and delaying access to essential treatments and vaccines.

Pregnant and postpartum women have an increased risk of developing TB compared with the general population. Moreover, TB disease in pregnancy is also associated with an increased risk of maternal morbidity, complications during birth, and perinatal morbidity and mortality. TB disease puts neonates born to mothers with TB at higher risk of the disease.

“The benefits of TB research must flow to all people with TB, including pregnant and lactating women,” said Dr Tereza Kasaeva, Director of the WHO Department for HIV, TB Hepatitis, and Sexually Transmitted Infections.

“It is time to prioritise their inclusion-not as an afterthought, but as a fundamental step toward equitable, evidence-based care,” Kasaeva said.

The WHO also released a Consensus Statement, which outlines a comprehensive framework to ensure equitable access to TB innovations for all, including those most at risk. Prepared by over 80 global experts, it covers five themes: preclinical TB research, TB therapeutics research, TB vaccine trials, maternal TB surveillance, and advocacy.